DHL Opens Dublin Facility Supporting Tech and Healthcare Growth

  • The new facility harnesses renewable energy and sustainable solutions, achieving BREEAM ‘Excellent’ and LEED ‘Gold’ classification

DHL Supply Chain today announces the opening of a new multi-user facility in Dublin, as part of the €637 million investment into the UK & Ireland region. The site is optimised for customers in the technology, life sciences and healthcare sectors, and delivers a range of specialist services.

These sectors are growing at pace, with a strong presence in Ireland which is host to 9 of the top 10 global software companies and 20 of the top 25 pharmaceutical companies in the world. The new Dublin-based site leverages DHL’s specialist services to directly address the unique needs of businesses in these industries.

From expert compliance support to customs clearance tools to full supply chain visibility, DHL delivers the right programmes and solutions to enable seamless operations and informed decision-making at all stages. For example, life sciences and healthcare customers at the new site benefit from the guarantee of zero time out of refrigeration for relevant products, with unloading docks sealed to vehicles. This enables temperature to be fully maintained at all times, an innovative feature which sets an industry standard.

Designed with sustainability at the fore, the building is certified as BREEAM ‘Excellent’ and LEED ‘Gold’, featuring several sustainable solutions including solar panels. The fleet operating out of the Dublin facility also harnesses renewable energy with a mix of electric vehicles and biomethane trucks helping to minimise carbon emissions on the road. DHL is also delivering innovative circular solutions, enabling DHL and its customers to extend the value and lifespan of products, reducing environmental impact by returning, recovering and reusing materials wherever possible.

With over 265,000 square feet of operating space, including 60,000 square feet of mezzanine flooring and 33,000 pallet spaces, the facility is located at the Quantum Distribution Park in Kilshane. The site and its customers benefit from strong transport links, situated close to Dublin Airport, Dublin Inland Port and Dublin Port.

Patrick Corbett, Managing Director Ireland, DHL Supply Chain says, “As the technology, life sciences and healthcare sectors continue to scale rapidly in Ireland, we are delighted to be opening a cutting-edge facility that caters to their needs with our specialist services. These are sectors which need flexible and resilient operations and our innovative supply chain solutions help them to maximise growth opportunities while minimising risk. The new site has been designed with longevity in mind, building in sustainable solutions across warehousing and transport.”

Peter Burke TD, Minister for Enterprise, Tourism and Employment said: “DHL’s latest investment in Ireland marks a bold step towards the future of sustainable and high-tech logistics. By embracing innovation and sustainability, DHL is not just expanding its footprint but setting new standards for the industry. DHL’s investment in their cutting-edge Quantum facility will support our drive to build on our nation’s international competitiveness.”

Michael Lohan, CEO of IDA Ireland said: ‘’DHL’s announcement further cements Ireland’s position as a leading location for global firms in the supply chain industry. This new facility demonstrates DHL’s further commitment to embedding themselves in our vibrant business community.’’

Read Similar…

New Facility in Vianen for FedEx

UPS Healthcare accelerates cold chain capabilities

UPS is expanding its specialty pharmaceutical offerings by establishing UPS Cold Chain Solutions, a comprehensive suite of cold chain technologies, best-in-class capabilities, and new and expanded global facilities providing complete, end-to-end temperature-controlled logistics.

“Our customers have been taking advantage of our cold chain capabilities for years, but the pandemic caused UPS to move even faster to enhance an integrated set of cold chain solutions to support the future of the pharmaceutical and medical device industry,” said Wes Wheeler, UPS Healthcare president. “UPS’s near-perfect, on-time delivery of the COVID-19 vaccine proves how effectively and efficiently our network handles biologically derived drugs, even at extreme temperatures.”

Chronic and life-threatening diseases, including cancers, respiratory, autoimmune and cardiovascular conditions, are the fastest growing disease categories in the world, creating a rapid acceleration in the development of biologically derived, temperature-controlled drugs and therapies.

According to the Biopharma Cold Chain Sourcebook, cold chain trends show 48% growth between 2018 and 2024 for drugs that require at least 2-8°C storage and shipping. Additionally, the overall market for cold chain services (packaging, transportation and data services) is expected to significantly accelerate growth over the next three years, growing by 24% by 2024, after posting a 10% increase from 2019 to 2020.

“The future of the healthcare and specialty pharmaceutical industries will increasingly rely on robust cold chain networks to safely deliver temperature-controlled drugs and therapies to customers,” said Kate Gutmann, UPS chief sales and solutions officer and SVP, UPS Global Healthcare. “The continued evolution of our cold chain offerings ensures UPS is ready for the future and can continue to provide long-term value for our healthcare customers.”

UPS Cold Chain Solutions is purpose-built to provide pharmaceutical companies, healthcare providers and laboratories a full, end-to-end cold chain service offering, including storage and distribution, transportation, visibility, and quality assurance capabilities to meet their complex demands for critical products around the world.

As part of a continued, aggressive strategy to build sophisticated capabilities in cold chain logistics, UPS Healthcare is expanding and augmenting its temperature-controlled products and services, including:

Cold chain GMP storage capacities – roughly 390,000 sq ft (36,200 sq m) of coolers and freezers installed at UPS facilities to support the storage of biologics ranging from 2°C to as low as -80°C

Packaging customisation – recommendations for specific temperature-controlled packaging options to minimise total cost while ensuring safe and efficient transportation of products

UPS European cold chain ground network expansion – adding more ground transportation fleets, better connection between gateways and teams of experts to create customisable solutions that fit our customers’ needs

Transportation efficiencies – four flexible, temperature-regulated service options via air or ocean freight that can be configured to meet the needs of the pharmaceutical packaging and help keep customer costs down

Precise monitoring with UPS Premier technology – protocols to provide pinpoint visibility into covered pallets, boxes, trailers and packages within 10ft       (3m) of their location anywhere in the UPS network

Facility updates – construction of two new GDP-compliant, healthcare-licensed distribution facilities in Italy and Australia, as well expansions and cold chain retrofit projects to facilities in The Netherlands, Czechia, Poland, Hungary and the US

“UPS sets a high bar for excellence in cold chain delivery and logistics, and these current and future investments in innovative solutions will ensure we keep pushing the bar higher,” Wheeler said. “For our customers, we will remain focused on delivering on our commitment to ‘Quality Focused. Patient Driven.’”

Subscribe

Get notified about New Episodes of our Podcast, New Magazine Issues and stay updated with our Weekly Newsletter.